OKYO Pharma Limited (OKYO)

Market Cap	75.05M -0.2%
Revenue (ttm)	n/a
Net Income	-8.95M
EPS	-0.24
Shares Out	52.48M
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	48,888
Open	1.420
Previous Close	1.415
Day's Range	1.400 - 1.460
52-Week Range	1.265 - 3.200
Beta	-0.06
Analysts	Strong Buy
Price Target	8.33 (+482.52%)
Earnings Date	Jul 20, 2026

About OKYO

OKYO Pharma Limited, a clinical-stage ophthalmology company, develops therapies for corneal and anterior diseases in the United Kingdom. Its lead clinical product candidate is urcosimod, which is in Phase 2 clinical trials for the treatment of dry eye disease and neuropathic corneal pain. The company is also developing OK-201 for the treatment of acute and chronic ocular pain. OKYO Pharma Limited was incorporated in 2007 and is headquartered in London, the United Kingdom.

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 17, 2022
• Employees: 5
• Stock Exchange: Nasdaq
• Ticker Symbol: OKYO
• Website: https://okyopharma.com

Analyst Summary

According to 3 analysts, the average rating for OKYO stock is "Strong Buy." The 12-month stock price target is $8.33, which is an increase of 482.52% from the latest price.

Price Target

$8.33

(482.52% upside)

Analyst Consensus: Strong Buy

Data Sources: S&P Global Market Intelligence, CBOE, and more

Fundamental and historical data is provided by S&P Global Market Intelligence. Real-time stock price data is provided by CBOE and 15-minute delayed consolidated tape pricing data is provided by Nasdaq UTP.

Last checked:

Oct 16, 2026

Data Sources Report a data error